Clinical trials: in Algeria
Type2 Diabetes Mellitus, Complications
Morbidity in Newly Diagnosed type2 Diabetes in Adults
It is a prospective,observational, cohort study The main purpose of the study is to assess the prevalence of diabetic chronic complications in newly diagnosed type 2 diabetics in suburban area of Algiers.
- Trial name
- MORNDIAB (NCT02002091)
- Testing
- no specific treatment
- Where
- Algeria
- Volunteers
- 327 people
- Sponsor
- University of Algiers
Metastatic Renal Cell Carcinoma
Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.
OPTIMISE is designed to provide knowledge regarding the use of Sunitinib as 1st line treatment and 2nd line treatment selected (Sunitinib-different sequence) with respect to efficacy outcomes, adverse events, and health related…
- Trial name
- OPTIMISE (NCT03140176)
- Testing
- Sunitinib
- Where
- 8 sites in Algeria, Egypt and 2 more
- Volunteers
- 77 people
- Sponsor
- Pfizer
Asthma, Chronic Obstructive Pulmonary Disease
Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID.
Interventional, Prospective, National, Multicentre, Randomised, Open-label, Controlled Clinical Study Comparing Two Parallel Groups, One Control Arm (Standard Treatment) Versus Intervention Arm (Standard Treatment + Study…
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, Long COVID
- Trial name
- NCT05601180
- Testing
- Respicure®, Standard of care
- Where
- 8 sites in Algeria
- Volunteers
- 402 people
- Sponsor
- Beker Laboratories
Schizophrenia
Using Speech to Monitor Symptom Severity in Arabic Speaking Patients With Schizophrenia
Brief Summary: Definition: A short description of the clinical study, including a brief statement of the clinical study's hypothesis, written in language intended for the lay public. Limit: 5000 characters.
- Trial name
- NCT05563818
- Testing
- WinterLight Mobile Phone Speech Analysis
- Where
- 4 sites in Algeria, Egypt and 2 more
- Volunteers
- 57 people
- Sponsor
- Hikma Pharmaceuticals LLC
Relapsing Remitting Multiple Sclerosis
Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region
The purpose of this observational study is to evaluate the effectiveness, safety and health related quality of life of Generic DMF (Sclera® or Marovarex ®, Hikma) in patients undergoing routine clinical care for RRMS in MENA…
- Trial name
- NCT04468165
- Testing
- Dimethyl Fumarate (DMF)
- Where
- 6 sites in Algeria, Egypt and 1 more
- Volunteers
- 160 people
- Sponsor
- Hikma Pharmaceuticals LLC
Thyroid Neoplasms
An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors
The purpose of the study was to assess the use of Multikinase Inhibitors (MKIs) in the treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAI) who do not have any…
- Trial name
- RIFTOS MKI (NCT02303444)
- Testing
- Sorafenib (Nexavar, BAY43-9006), Other Multikinase inhibitors
- Where
- 34 sites in United States, Algeria and 17 more
- Volunteers
- 667 people
- Sponsor
- Bayer
Diabetes Mellitus
GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups
Evaluation of safety and effectiveness of Glucobay® under daily-life treatment conditions in a large sample of patients.
- Trial name
- NCT00909051
- Testing
- Acarbose (Glucobay, BAYG5421)
- Where
- 16 sites in Algeria, Bosnia and Herzegovina and 14 more
- Volunteers
- 15,729 people
- Sponsor
- Bayer
Multiple Myeloma, Renal Failure
High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal Impairment
Multiple myeloma (MM) is a malignant plasma cell disorder, characterized by the presence of more than 10 % of clonal plasma cells in the bone marrow.
- Trial name
- IRMYG (NCT03234335)
- Testing
- Data collection
- Where
- 33 sites in Algeria, Belgium and 2 more
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Chronic Hepatitis C Virus (HCV) Infection Genotype 1
A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
The purpose of this study was to evaluate the effect of treatment with ABT-450 co-formulated with ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333; 3-DAA regimen, with or without ribavirin (RBV) in adults with chronic…
- Trial name
- TOPAZ-I (NCT02219490)
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV)
- Where
- 187 sites in Algeria, Australia and 25 more
- Volunteers
- 1,596 people
- Sponsor
- AbbVie
Oncology, Epidemiology
Epidemiology of Breast Cancer in Women Based on Diagnosis Data From Oncologists and Breast Surgeons in Algeria
National, prospective, multicentre, non-interventional epidemiological study, conducted among oncologists and breast surgeons in community and university hospitals, from the public sector in Algeria.
- Conditions
- Oncology, Epidemiology, Breast Cancer
- Trial name
- BreCaReAl (NCT02733601)
- Testing
- NIS (Non Interventional Study) observational study
- Where
- 3 sites in Algeria
- Volunteers
- 1,500 people
- Sponsor
- AstraZeneca
Breast Neoplasm Female
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant
This is a multicenter, international, double-blind randomized Phase III study to evaluate the pathological complete response (pCR) according to Chevalier classification between Fulvestrant® and the combination of Fulvestrant®…
- Trial name
- SAFIA (NCT03447132)
- Testing
- Fulvestrant 500mg, Palbociclib 125mg, Goserelin 3.6 MG
- Where
- 14 sites in Algeria, Egypt and 6 more
- Volunteers
- 354 people
- Sponsor
- International Cancer Research Group, United Arab Emirates
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of the trial is to investigate the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes.
- Trial name
- PIONEER 6 (NCT02692716)
- Testing
- semaglutide
- Where
- 228 sites in United States, Algeria and 19 more
- Volunteers
- 3,183 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only.
- Trial name
- PIONEER 1 (NCT02906930)
- Testing
- semaglutide
- Where
- 105 sites in United States, Algeria and 9 more
- Volunteers
- 703 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings
DISCOVER is a Non Interventional Study study to describe the disease management patterns and clinical evolution over three years in type 2 diabetes mellitus patients initiating a second line anti-diabetic treatment.
- Trial name
- DISCOVER (NCT02322762)
- Where
- 303 sites in Algeria, Argentina and 30 more
- Volunteers
- 15,992 people
- Sponsor
- AstraZeneca
Relapsing Multiple Sclerosis (RMS)
Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)
This is an open label, non randomized, uncontrolled, multicenter, single arm observational study. In this study, the enrolled subjects will be treated with Rebif human serum albumin (HSA)-free formulation (with or without…
- Trial name
- NCT02921035
- Testing
- Rebif (Interferon beta-1a)
- Where
- 41 sites in Algeria, Argentina and 11 more
- Volunteers
- 594 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Oncology & Epidemiology & Lung Cancer
National Lung Cancer Registry in Men and Women Based on Diagnosis in Algeria
National, prospective, multicentric, non-interventional registry-based study, conducted among oncologists, pulmonologists in community and university hospitals, from the public sector in Algeria.
- Trial name
- LuCaReAl (NCT02725892)
- Testing
- NIS observational stud
- Where
- 3 sites in Algeria
- Volunteers
- 897 people
- Sponsor
- AstraZeneca
Chronic Hepatitis c
Evaluation of the Efficacy and Safety of the Fixed-dose Combination Sofosdac® 400mg/60mg in Patients With Chronic Hepatitis C (HCV)
A multicentric, observational, open-design study conducted to evaluate the efficacy and safety of Sofosdac® 400mg/60mg tablets treatment in 100 patients with chronic hepatitis C (HCV)
- Trial name
- NCT05138523
- Testing
- Sofosdac®
- Where
- 4 sites in Algeria
- Volunteers
- 99 people
- Sponsor
- Beker Laboratories
Haemophilia A, Haemophilia A With Inhibitors
A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6)
This study will collect data on bleeds and data related to quality of life in people with severe congenital (a disease existing from birth) haemophilia A and B, with or without inhibitors.
- Conditions
- Haemophilia A, Haemophilia A With Inhibitors, Haemophilia B, Haemophilia B With Inhibitors
- Trial name
- explorer™6 (NCT03741881)
- Testing
- No treatment given
- Where
- 143 sites in United States, Algeria and 34 more
- Volunteers
- 231 people
- Sponsor
- Novo Nordisk A/S
Cervical Cancer
Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom
The objective of the present study is to estimate the overall survival of patients with cervical cancer after the administration of monoclonal antibody (mAb) Nimotuzumab (hR3) in combination with chemotherapy of first intention.
- Trial name
- CIMAHOPE (NCT03413579)
- Testing
- Nimotuzumab ( h-R3)
- Where
- 5 sites in Algeria
- Volunteers
- 37 people
- Sponsor
- El Kendi Pharmaceuticals Manufacturing Company
Breast Neoplasms
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
This multicenter, two-cohort, non-randomized, open-label study will evaluate the safety and tolerability of assisted and self-administered SC Herceptin as adjuvant therapy in participants with early HER2-positive breast cancer…
- Trial name
- SafeHER (NCT01566721)
- Testing
- Herceptin
- Where
- 437 sites in Albania, Algeria and 57 more
- Volunteers
- 2,577 people
- Sponsor
- Hoffmann-La Roche